Calamos Advisors LLC cut its holdings in Humana Inc. (NYSE:HUM - Free Report) by 15.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,400 shares of the insurance provider's stock after selling 5,575 shares during the period. Calamos Advisors LLC's holdings in Humana were worth $11,218,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. BlackRock Inc. bought a new stake in Humana during the second quarter worth $4,138,160,000. Pzena Investment Management LLC bought a new position in Humana in the 2nd quarter valued at $1,749,014,000. Assenagon Asset Management S.A. grew its stake in Humana by 20,126.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider's stock valued at $479,053,000 after purchasing an additional 1,249,272 shares during the period. Legal & General Group Plc purchased a new stake in shares of Humana during the 2nd quarter valued at $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of Humana during the 2nd quarter valued at $314,922,000. 92.38% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts recently weighed in on the stock. Lake Street Capital initiated coverage on shares of Humana in a research report on Thursday, July 30th. They set a "buy" rating for the company. Bank of America upgraded shares of Humana from a "neutral" rating to a "buy" rating and set a $500.00 price objective for the company in a report on Wednesday, July 29th. Evercore raised shares of Humana from an "in-line" rating to an "outperform" rating and set a $480.00 price objective on the stock in a research report on Wednesday, July 29th. HSBC cut shares of Humana to a "hold" rating in a research note on Thursday, July 30th. Finally, Raymond James Financial reissued an "outperform" rating on shares of Humana in a research report on Friday. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $458.96.
View Our Latest Analysis on Humana
Key Headlines Impacting Humana
Here are the key news stories impacting Humana this week:
Humana Trading Up 5.1%
Shares of HUM opened at $432.69 on Friday. The business has a 50-day moving average of $403.96 and a 200 day moving average of $312.27. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $456.50. The firm has a market cap of $51.96 billion, a P/E ratio of 42.09, a price-to-earnings-growth ratio of 2.67 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74.
Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.30. The business had revenue of $41.16 billion for the quarter, compared to analysts' expectations of $40.87 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%. The firm's quarterly revenue was up 26.1% compared to the same quarter last year. During the same period in the previous year, the business posted $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, research analysts forecast that Humana Inc. will post 9.03 EPS for the current year.
Humana Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be paid a $0.8850 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Thursday, December 24th. Humana's payout ratio is currently 33.49%.
About Humana
(
Free Report)
Humana Inc is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.
The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Humana was founded in 1961 as a nursing home company and later expanded into health insurance.
See Also
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.